Cailin Conner

Urban Health Today

A study in the World Allergy Organization Journal found that omalizumab “may be successfully withdrawn in up to 50% of severe [chronic spontaneous urticaria (CSU)] patients following complete remission of disease symptoms.”
The study, conducted over a 6-year period, examined patients with severe CSU who were eligible for omalizumab treatment. Out of 335 patients with CSU included in the analysis, 192 were categorized as severe and thus qualified for omalizumab therapy. Of these, 131 patients responded positively to omalizumab, and 95 achieved complete remission for more than 6 months, making them eligible for withdrawal from omalizumab treatment.
Successful withdrawal of omalizumab was achieved in 49.5% of patients who underwent the withdrawal process. A total of 50.5% of patients experienced a flare of symptoms upon omalizumab withdrawal.
Certain biomarkers were found to be associated with the outcomes of omalizumab withdrawal. According to the results, successful withdrawal was associated with a relatively shorter duration of disease (7.1 vs 10.7 years; P=.042), lower baseline immunoglobulin E (IgE) levels (81.6 vs 324.7 IU/ml; P=.005), and lower baseline number of blood eosinophils (131.4 vs 195.6; P=.043).
Furthermore, omalizumab withdrawal failure “was almost doubled if baseline IgE was &gt;90 IU/ml and/or blood eosinophils &gt;0.15 × 109/L.”
“This study presents plausible markers to predict [omalizumab] withdrawal outcomes,” the investigators wrote. They went on to state that, “we believe that our meticulous follow-up and examination by a specialist using the same treatment algorithm for all patients enabled us to present valuable real-life data that can be reproducible and enable physicians to better tailor CSU therapy.”
Source: <a href="https://www.worldallergyorganizationjournal.org/article/S1939-4551(24)00036-X/fulltext" target="_blank" rel="noopener">World Allergy Organization Journal</a>

A study in the World Allergy Organization Journal found that omalizumab “may be successfully withdrawn in up to 50% of severe [chronic spontaneous urticaria (CSU)] patients following complete remission of disease symptoms.”The study, conducted over a 6-year period, examined patients with severe CSU who were eligible for omalizumab treatment. Out of 335 patients with CSU included in the analysis, 192 were categorized as severe and thus qualified for omalizumab therapy. Of these, 131 patients responded positively to omalizumab, and 95 achieved complete remission for more than 6 months, making them eligible for withdrawal from omalizumab treatment.Successful withdrawal of omalizumab was achieved in 49.5% of patients who underwent the withdrawal process. A total of 50.5% of patients experienced a flare of symptoms upon omalizumab withdrawal.Certain biomarkers were found to be associated with the outcomes of omalizumab withdrawal. According to the results, successful withdrawal was associated with a relatively shorter duration of disease (7.1 vs 10.7 years; P=.042), lower baseline immunoglobulin E (IgE) levels (81.6 vs 324.7 IU/ml; P=.005), and lower baseline number of blood eosinophils (131.4 vs 195.6; P=.043).Furthermore, omalizumab withdrawal failure “was almost doubled if baseline IgE was &gt;90 IU/ml and/or blood eosinophils &gt;0.15 × 109/L.”“This study presents plausible markers to predict [omalizumab] withdrawal outcomes,” the investigators wrote. They went on to state that, “we believe that our meticulous follow-up and examination by a specialist using the same treatment algorithm for all patients enabled us to present valuable real-life data that can be reproducible and enable physicians to better tailor CSU therapy.”Source: <a href="https://www.worldallergyorganizationjournal.org/article/S1939-4551(24)00036-X/fulltext" target="_blank" rel="noopener">World Allergy Organization Journal</a>

Lou Portero

Autoimmune Diseases Double Mental Health Risk, Especially for Women

Women's Neurology

Nearly 30% of Medical Students Now Pursuing DO Degrees

Workforce News

Women's Health Initiative at 30: Three Decades of Evidence Reshape Postmenopausal Care

Menopause

Latest News

Lower Baseline IgE Levels, Shorter Disease Duration Linked to Successful Withdrawal of Omalizumab for Severe CSU

Chronic Spontaneous Urticaria

Successful withdrawal of omalizumab was achieved in approximately 49.5% of patients with severe CSU. 

Lower Baseline IgE Levels, Shorter Disease Duration Linked to Successful Withdrawal of Omalizumab 